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Disorders of the extrahepatic bile ducts carry significant morbidity and 1 
mortality. Indeed, 70% of pediatric liver transplantations are performed to treat 2 
biliary atresia (1), Primary Sclerosing Cholangitis (PSC) alone accounts for 3 
5% of US liver transplantations (2) and biliary complications are the leading 4 
cause of graft failure following deceased liver transplantation (3,4). Treatment 5 
options remain limited (5,6) due to the lack of healthy tissue that can be used 6 
to reconstruct and replace diseased bile ducts. In vitro expansion of native 7 
cholangiocytes could address this challenge and provide cells suitable for 8 
tissue engineering applications such as biliary reconstruction. However, the 9 
culture of primary biliary epithelium remains problematic (7). Here we report a 10 
novel method for the isolation and propagation of primary human 11 
cholangiocytes from the extrahepatic biliary tree, compatible with regenerative 12 
medicine applications. The resulting Extrahepatic Cholangiocyte Organoids 13 
(ECOs) express key biliary markers such as CK7, CK19, GGT, CFTR and 14 
maintain their functional properties in vitro including ALP, GGT activity and 15 
responses to secretin and somatostatin. The potential of ECOs for tissue 16 
engineering and clinical applications is further illustrated by their capacity to 17 
populate biodegradable scaffolds, organize into a functional biliary epithelium 18 
and rescue a murine model of extrahepatic biliary injury (EHBI). 19 
To establish this system, we first focused on identifying optimal conditions to 20 
isolate primary cholangiocytes from the biliary epithelium which forms a 21 
monolayer covering the luminal surface of the biliary tree (8). We tested 22 
several approaches for recovering these cells and mechanical dissociation by 23 
brushing or scraping the bile duct lumen was associated with improved 24 
survival compared to enzymatic digestion (Figure 1a, Supplementary Fig. 1a). 25 
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Furthermore, the majority of the resulting cells co-expressed the biliary 1 
markers Cytokeratin 7 (CK7) and Cytokeratin 19 (CK19) (94.6 ± 2.4% (SD; 2 
n=3); while no contamination from mesenchymal cell types was detected. 3 
(Supplementary Fig 2). Consequently, mechanical dissociation constitutes the 4 
optimal method for harvesting extrahepatic cholangiocytes.  5 
To discern appropriate conditions for the maintenance and propagation of 6 
these cells, we optimized our recently established system for 3D culture of 7 
human induced pluripotent stem cell-derived intrahepatic cholangiocytes (9). 8 
Screening of multiple growth factors known to support expansion of 9 
cholangiocytes and epithelial organoids (10,11) (Supplementary Fig 1b-1c) 10 
identified that the combination of Epidermal Growth Factor (EGF), R-Spondin 11 
and Dickkopf-related protein 1 (DKK-1) promoted the growth of primary 12 
cholangiocytes into organoids (Figure 1b, 1c). Due to the paradoxical 13 
requirement for both a Wnt potentiator (R-spondin) and an inhibitor (DKK-1), 14 
we characterized the canonical and non-canonical/PCP Wnt pathway activity 15 
in ECOs. Our results demonstrate increased levels of β-catenin 16 
phosphorylation (Supplementary Fig. 1d-1e), signifying reduced WNT 17 
canonical pathway activity in ECOs, as well as increased Rho Kinase activity 18 
(Supplementary Fig. 1f), which could be consistent with enhanced non-19 
canonical/PCP signaling in ECOs. Thus, it is possible that non-canonical Wnt 20 
signaling controls ECO expansion marking a significant difference with 21 
previous organoid culture conditions (11). 22 
Under these conditions, we derived 8 different ECO lines (Supplementary 23 
Table 1) from a variety of deceased donors aged from 33 to 77 years. 24 
Importantly, we obtained similar results by using cholangiocytes isolated from 25 
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the gallbladder or by harvesting common bile duct cholangiocytes using an 1 
Endoscopic Retrograde Cholangio-Pancreatography (ERCP) brush instead of 2 
scrapping the lumen (Supplementary Fig 3). Consequently, ECOs can be 3 
derived from different areas of the extra-hepatic biliary tree and harvested 4 
using peri-operative (dissection and scrapping) or minimally invasive (ERCP 5 
brushings) approaches. 6 
The resulting cells were expanded in vitro for prolonged periods of time 7 
(Supplementary Fig 4a) while maintaining their genetic stability 8 
(Supplementary Fig 4b-4c). Electron microscopy revealed the presence of 9 
characteristic ultrastructural features including cilia, microvilli and tight 10 
junctions (12) (Figure 1d, Supplementary Fig 5), while QPCR and 11 
immunofluorescence (IF) analyses established the expression of key biliary 12 
markers such as CK7, CK19, Hepatocyte Nuclear Factor-1-beta (HNF1B), 13 
Gamma Glutamyl-Transferase (GGT), Secretin Receptor (SCR), sodium-14 
dependent bile acid transporter (ASBT/SLC10A2), Cystic fibrosis 15 
transmembrane conductance regulator (CFTR) and Sox9 (9) (Figure 1e-1f, 16 
Supplementary Fig 3c-3d, 6a-6b). Importantly, stem cell markers (POU5F1, 17 
NANOG, PROM1, LGR-4/5/6), markers of non-biliary lineages (albumin, α1-18 
antitrypsin, CK18, PDX1, insulin and glucagon) and EMT markers (vimentin, 19 
SNA1L and S100A4) were not detected (Supplementary Fig 7a-7c). On the 20 
other hand, 98.1% ± 0.9% (SD; n=3) of the cells co-expressed CK7 and CK19 21 
following 20 passages (Supplementary Fig 2) thereby confirming the presence 22 
of a near homogeneous population of cholangiocytes.  23 
Transcriptomic analyses (Figure 1g, Supplementary Fig. 8, Supplementary 24 
Table 2) revealed that ECOs maintain a stable gene expression profile over 25 
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multiple passages (Pearson correlation coefficient for Passage 1 (P1) vs. 1 
Passage 20 (P20) r=0.99, Supplementary Fig 8a-b), express key biliary 2 
markers and cluster closely to freshly isolated cholangiocytes (Pearson 3 
correlation coefficient for Primary Cholangiocytes (PCs) vs. Passage 20 (P20) 4 
r=0.92; Figure 1g, Supplementary Fig 8b-8d). Gene ontology analyses 5 
confirmed enrichment of pathways characteristic for the biliary epithelium 6 
(Supplementary Fig 8e). Considered collectively, these results demonstrate 7 
that primary cholangiocytes derived from the extrahepatic biliary tree can be 8 
expanded in vitro without losing their original characteristics. 9 
We then decided to further characterize ECOs by focusing on their function 10 
following long term culture (20 passages). The biliary epithelium regulates the 11 
homeostasis of bile through the transport of ions, water and bile acids (8,13). 12 
The secretory capacity of ECOs was interrogated using Rhodamine-123, a 13 
fluorescent substrate for the cholangiocyte surface glycoprotein Multidrug 14 
Resistance protein-1 (MDR1) (14,15) (Figure 2a-2c). Rhodamine-123 15 
accumulated in the ECO lumen only in the absence of the MDR-1 antagonist 16 
verapamil, thereby confirming active secretion through MDR-1 (Figure 2a-2c). 17 
Luminal extrusion of bile acids (16) was also demonstrated by showing that 18 
the fluorescent bile acid Cholyl-Lysyl-Fluorescein (CLF) was actively exported 19 
from ECOs (Figure 2d-2f). Furthermore, ECO ALP and GGT activity was 20 
comparable to freshly plated primary cholangiocytes (Figure 2g-2h, 21 
Supplementary Fig. 3e-3f). The response of ECOs to secretin and 22 
somatostatin was also assessed. Secretin promotes water secretion, 23 
distending the bile duct lumen, while somatostatin negates the effects of 24 
secretin (17–19). Accordingly, organoids exposed to secretin increased their 25 
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diameter compared to untreated controls, while somatostatin inhibited the 1 
effect of secretin (Figure 2i-2j). Our data, therefore, demonstrate that ECOs 2 
maintain their functional properties after long term culture. 3 
These results prompted us to investigate the interest of ECOs for in vivo use, 4 
especially regenerative medicine applications. We first characterized the 5 
potential of ECOs for in vivo engraftment and survival by transplanting cells 6 
under the kidney capsule of NOD.Cg-Prkdcscid Il2rgtm1Wjl (NSG) mice 7 
(Supplementary Fig 9a) for 12 weeks (20). ECOs successfully engrafted 8 
forming tubular structures expressing biliary markers such as CK19 9 
(Supplementary Fig 9b-d). Importantly, no tumour formation or markers of 10 
differentiation to other lineages were detected (Supplementary Fig 9d). Thus, 11 
ECOs appear to maintain their basic characteristics even after prolonged 12 
engraftment in vivo under the kidney capsule.  13 
Following these encouraging results, we decided to define the capacity of 14 
ECOs to repair the biliary epithelium. For that, we developed a mouse model 15 
of extrahepatic biliary injury (EHBI). More specifically, to simulate biliary tree 16 
wall defects requiring biliary reconstruction (21), the biliary tree of healthy 17 
NSG mice was compromised through a longitudinal incision in the gallbladder 18 
wall (Figure 3a). We then generated a bioengineered tissue patch to repair 19 
this injury by populating Polyglycolic Acid (PGA) biodegradable scaffolds with 20 
either GFP-expressing ECOs (Supplementary Fig 10-12, Supplementary 21 
Note) or GFP-expressing fibroblasts (Supplementary Fig 13a-13d). The 22 
resulting bioengineered tissue was subsequently transplanted into the injured 23 
animals to close the wall defect created by surgery. Animals receiving 24 
acellular scaffolds died within 24 hours of the operation (Figure 3b) and post-25 
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mortem examination revealed yellow pigmentation of the peritoneal cavity and 1 
seminal vesicles  consistent with bile leak (Supplementary Fig 14a); while all 2 
animals in fibroblast-scaffold group failed to reconstruct their gallbladder 3 
which was replaced by fibrotic tissue incompatible with bile transport or 4 
storage (Supplementary Fig 13e-13g). In contrast, animals transplanted with 5 
scaffolds containing ECOs survived for up to 104 days without complications 6 
and were culled electively (Figure 3b). Importantly, the reconstructed 7 
gallbladders in the ECO group were fully remodeled resembling the 8 
morphology of their native counterparts (Figure 3c, Supplementary Fig 14b). 9 
Histology (Figure 3d), IF and QPCR analyses of the ECO-reconstructed 10 
gallbladders (Figure 3e, Supplementary Fig 14c-14d) unveiled integration of 11 
GFP-positive ECOs expressing biliary markers, such as CK19, CK7, HNF1B, 12 
Sox9, CFTR and a human-specific epitope for Ku80 (Figure 3e, 13 
Supplementary Fig 14c). Importantly, these IF analyses also showed the 14 
presence of mouse mesenchymal cells expressing vimentin and endothelial 15 
cells expressing CD31 in the reconstructed biliary epithelium suggesting that 16 
the scaffold is colonized by endogenous cells after transplantation 17 
(Supplementary Fig 14c). Interestingly, we also identified a population of 18 
GFP+/vimentin+/CK19- cells, suggesting that ECOs may also contribute to 19 
the scaffold stroma; possibly through epithelial to mesenchymal transition 20 
(EMT; Supplementary Fig 14c, 14e). The integrity of the reconstructed 21 
gallbladder lumen and its exposure to bile through continuity with the biliary 22 
tree were demonstrated using Magnetic Resonance Cholangio-23 
Pancreatography (MRCP) imaging prior to removal of the organ and was 24 
further confirmed with FITC cholangiograms (Figure 3f-3g, Supplementary Fig 25 
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14f, Supplementary Video 1). Post mortem surgical examination and full body 1 
Magnetic resonance Imaging 104 days post transplantation revealed no 2 
evidence of tumor formation (Supplementary Fig 14f, Supplementary Video 2) 3 
while IF analyses revealed no GFP+ cells in the adjacent liver tissue (data not 4 
shown). On the contrary, gallbladders reconstituted with fibroblasts controls 5 
exhibited obliteration of the gallbladder lumen (Supplementary Fig 13h-13i) 6 
and replacement of the lumen and biliary epithelium by fibroblasts expressing 7 
Fibroblast Specific Antigen S100A4 (Supplementary Fig. 13i-13j). Considered 8 
collectively, our findings demonstrate the capacity of ECOs to colonize their 9 
physiological niche and regenerate part of the biliary tree without any 10 
complications. 11 
Reconstruction of the gallbladder wall provided proof-of-principle for the 12 
capacity of ECOs to regenerate the biliary epithelium after injury; however, the 13 
majority of extrahepatic bile duct disorders affect the common bile duct (CBD). 14 
Therefore we decided to explore the possibility to replace the native CBD of 15 
NSG mice with a bioengineered duct consisting of an ECO-populated 16 
densified collagen tube. (Supplementary results, Supplementary Fig 15, 16, 17 
Fig 4a). A mid-portion of the native CBD was removed and an ECO-populated 18 
collagen tube was anastomosed end-to-end to the proximal and distant duct 19 
remnants (n=4 animals). Fibroblast populated tubes were used as a negative 20 
control (n=4). Biliary reconstruction was achieved in all animals transplanted 21 
with ECO-populated tubes (Figure 4b-4c, Supplementary Fig 17a-17d), which 22 
were followed up for up to a month post transplantation (Supplementary Fig 23 
17d). Histology and IF analyses revealed a patent lumen, with formation of a 24 
biliary epithelium by the transplanted GFP+ cells (Figure 4e-4f, 25 
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Supplementary Fig 17a-17b). IF and QPCR analyses confirmed the 1 
expression of biliary markers, such as CK19, CK7, HNF1B, CFTR, Sox9 2 
(Figure 4d, 4f, Supplementary Fig 17b) by the engrafted cells but also 3 
illustrated the presence of mouse stromal and endothelial cells 4 
(Supplementary Fig 17b). Moreover, we observed minimal apoptosis and 5 
proliferation in the transplanted tubes 1 month after transplantation, 6 
confirming the stability and integrity of the reconstituted biliary epithelium 7 
(Supplementary Fig 17b-17c). Lumen patency was further confirmed by FITC-8 
cholangiogram and MRCP (Figure 4g, Supplementary Fig 17f) and all the 9 
animals receiving ECO-populated tubes exhibited no increase in serum 10 
cholestasis markers (Bilirubin, ALP; Supplementary Fig 17e) accordingly; 11 
while the bio-artificial common bile ducts retained their ALP activity in vivo 12 
(Figure 4h). On the contrary, all the fibroblast-populated collagen tubes failed 13 
due to lumen occlusion (Figure 4b-4c, 4e-4g, Supplementary Fig 17d), 14 
resulting in increased biliary pressures and bile leak through the site of 15 
anastomosis (Figure 4b). In conclusion, our results demonstrate the capacity 16 
of ECO-populated collagen tubes to replace the native CBD in vivo.  17 
In summary, we have demonstrated that epithelial cells from the extrahepatic 18 
biliary tree can be expanded and propagated in vitro while maintaining their 19 
cholangiocyte transcriptional signature and functional characteristics. In 20 
addition, our results show that primary cholangiocytes expanded in vitro as 21 
organoids have a unique potential for organ regeneration. Indeed, our system 22 
provides the first proof-of-principle for the application of regenerative medicine 23 
in the context of common bile duct pathology. The capacity to replace a 24 
diseased common bile duct with an in vitro bio-engineered ECO-tube could 25 
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have a significant impact for the management of disorders such as biliary 1 
atresia, which constitutes the leading cause for pediatric liver transplantation 2 
(1); or ischemic strictures which are one of the most common complications 3 
following transplantation (3). Consequently ECO-populated scaffolds 4 
constitute a novel system with increased clinical relevance in the field of 5 
cholangiopathies. 6 
Furthermore, studies of the extrahepatic biliary epithelium have been limited 7 
by technical challenges in long-term culture and significant expansion of 8 
primary cholangiocytes. These challenges have so far precluded large scale 9 
experiments such as transcriptomic and genome-wide analyses which are 10 
urgently needed to better understand bile duct diseases, such as PSC and 11 
cholangiocarcinoma. The capacity of ECOs for large scale expansion, could 12 
address this challenge. Indeed, we demonstrate that starting from 105 13 
extrahepatic cholangiocytes we can generate between 1020 – 1025 cells after 14 
20 passages. Therefore, ECOs not only represent a novel source of cells for 15 
cell based therapy but also provide a unique model system for studying the 16 
physiology and modeling disorders of the extrahepatic biliary tree in vitro. 17 
Access to human tissue constitutes a significant limitation for systems based 18 
on primary cells. However, we show that ECOs can be obtained not only from 19 
the common bile duct but also from the gallbladder. Gallbladder tissue is 20 
easily accessible and routinely discarded following liver transplantation and 21 
cholecystectomy, one of the most common surgical procedures performed. 22 
Furthermore, in patients not having surgery the common bile duct can be 23 
accessed using minimally invasive procedures, such as Endoscopic 24 
Retrograde Cholangio-Pancreatography (ERCP) and we demonstrate that 25 
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cholangiocytes can be obtained through brushings, which are routinely 1 
performed to acquire histology specimens. Importantly, no morphological or 2 
functional differences were observed between organoids obtained with these 3 
different methods. Moreover, due to the scalability of our system only a small 4 
amount of starting material is required. Finally, recent progress in replacing 5 
Matrigel by custom made hydrogels to grow gut organoids (22) suggest that 6 
translating our system from Matrigel to Good Manufacturing Practice (GMP) 7 
could be feasible. Considered together, these approaches address any issues 8 
of tissue availability and open the possibility of autologous as well as 9 
allogeneic cell based therapy.  10 
Importantly, the derivation of primary hepatic stem cells using an organoid 11 
culture system has been reported previously (11). However, the capacity of 12 
the resulting cells to differentiate into functional cholangiocytes and populate 13 
the biliary tree in vivo remains to be demonstrated. Furthermore, in vivo 14 
applications of such platforms could be restricted by contaminating stem cells 15 
with a capacity to proliferate inappropriately after transplantation and /or 16 
differentiate into non-biliary cell types. Importantly, despite the association 17 
between organoids and adult stem cells (23), we never observed the 18 
expression of hepatocyte or pancreatic markers during our experiments either 19 
in vitro or after transplantation, suggesting that the differentiation capacity of 20 
ECOs is limited to their lineage of origin. Moreover, canonical WNT signaling, 21 
which is crucial for the expansion of adult stem cell organoids (24) is blocked 22 
in our culture conditions through the use of DKK-1 and further studies may be 23 
required to fully elucidate the role of R-spondin in our system. Considered 24 
together, these observations suggest that our culture system does not include 25 
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a stem cell population. However, we cannot completely exclude that these 1 
cells could represent a biliary progenitor population based on their ability to 2 
self-propagate and generate organoids from single cells (Supplementary 3 
Video 3).  4 
In conclusion, our results open up novel avenues for the use of extrahepatic 5 
primary biliary tissue as a novel platform for in vitro studies, disease modeling 6 
and cell based therapy applications. 7 
  8 
15 
 
Online Methods 1 
Primary biliary tissue 2 
Primary biliary tissue (bile duct or gallbladder) was obtained from deceased 3 
organ donors from whom organs were being retrieved for transplantation. The 4 
gallbladder or a section of the bile duct was excised during the organ retrieval 5 
operation after obtaining informed consent from the donor’s family (REC 6 
reference numbers: 09/H0306/73, NRES Committee East of England – 7 
Norfolk, 12/EE/0253, NRES Committee East of England - Cambridge Central 8 
and 15/EE/0152 NRES Committee East of England - Cambridge South). 9 
Isolation of primary cholangiocytes 10 
Excised bile duct segments were placed in a 10cm plate and washed once 11 
with William’s E medium (Gibco, Life Technologies). A longitudinal incision 12 
was made along the wall of the excised bile duct segment exposing the lumen 13 
and 10-15ml of William’s E medium were added to cover the tissue. The 14 
luminal epithelium was subsequently scraped off using a surgical blade, while 15 
submerged in medium. The supernatant was collected and the tissue and 16 
plate were washed 2-3 times with William’s E medium to harvest any 17 
remaining cells. The supernatant and washes were centrifuged at 444g for 4 18 
minutes. The pellet was washed with William’s E, re-centrifuged and the 19 
supernatant was discarded (Figure 1a). 20 
Excised gallbladders were placed in a 15cm plate, a longitudinal incision was 21 
made along the wall of the excised gallbladder and the lumen was washed 22 
once with William’s E medium (Gibco, Life Technologies). Cholangiocytes 23 
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were isolated and harvested following the method described above 1 
(Supplementary Fig. 3a). 2 
For isolation through brushings, an excised bile duct segment was placed in a 3 
10cm plate and cannulated using an ERCP brush. The lumen was brushed 4 
10-20 times and the cells were harvested by washing the brush several times 5 
in a falcon tube containing 40-50 ml of William’s E medium (Supplementary 6 
Fig. 3b).  7 
Generation and culture of ECOs 8 
Isolated primary cholangiocytes were centrifuged at 444g for 4 minutes and 9 
re-suspended in a mixture of 66% matrigel (BD Biosciences, catalogue 10 
number: 356237) and 33% William’s E medium (Gibco, Life Technologies) 11 
supplemented with 10mM nicotinamide (Sigma-Aldrich), 17mM sodium 12 
bicarbonate (Sigma Aldrich), 0.2mM 2-Phospho-L-ascorbic acid trisodium salt 13 
(Sigma-Aldrich), 6.3mM sodium pyruvate (Invitrogen), 14mM glucose (Sigma-14 
Aldrich), 20mM HEPES (Invitrogen), ITS+ premix (BD Biosciences), 0.1µM 15 
dexamethasone (R&D Systems), 2mM Glutamax (Invitrogen),100U/ml 16 
penicillin per 100μg/ml streptomycin, 20ng/ml EGF (R&D Systems), 500ng/ml 17 
R-Spondin (R&D Systems) and 100ng/ml DKK-1 (R&D Systems). The cell 18 
suspension was plated in 24-well plate format, at 50μl/well, so that a small 19 
dome of matrigel was formed in the centre of each well and then incubated at 20 
37oC for 10-30 minutes until it solidified. Subsequently, 1ml of William’s E 21 
medium with supplements was added. The culture medium was changed 22 
every 48 hours.  23 
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To split the cells, the matrigel was digested by adding Cell Recovery Solution 1 
(Corning) for 30 minutes at 4oC. The resulting cell suspension was harvested, 2 
centrifuged at 444g for 4 minutes, washed once with William’s E medium and 3 
re-suspended in 66% matrigel and 33% William’s E medium with 4 
supplements, as described above. 5 
All experiments were performed using passage 20 ECOs unless otherwise 6 
stated. 7 
Cell line identity 8 
Demographic data for donor corresponding to the each ECO lines is provided 9 
in supplementary table 1. Following derivation ECO lines were authenticated 10 
by matching their karyotype (Supplementary Fig. 2c) to the sex of the donor of 11 
origin. The lines were tested on a regular basis and found to be negative for 12 
mycoplasma contamination.  13 
Immunofluorescence, RNA extraction and Quantitative Real Time PCR 14 
IF, RNA extraction and QPCR were performed as previously described (9). A 15 
complete list of the primary and secondary antibodies used is provided in 16 
supplementary table 3. A complete list of the primers used is provided in 17 
supplementary table 4.  18 
All QPCR data are presented as the median, interquartile range (IQR) and 19 
range (minimum to maximum) of four independent biological replicates. 20 
Values are relative to the housekeeping gene Hydroxymethylbilane Synthase 21 
(HMBS). 22 
All IF images were acquired using a Zeiss Axiovert 200M inverted microscope 23 
or a Zeiss LSM 700 confocal microscope. Imagej 1.48k software (Wayne 24 
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Rasband, NIHR, USA, http://imagej.nih.gov/ij ) was used for image 1 
processing. IF images are representative of at least 3 different experiments. 2 
IF images of reconstructed gallbladder sections are representative of 5 3 
different animals. 4 
Microarrays 5 
RNA for microarray analysis was collected from 3 different ECO lines (n=3). 66 
The RNA was assessed for concentration and quality using a SpectroStar 67 
(BMG Labtech, Aylesbury, UK) and a Bioanalyser (Agilent Technologies, 68 
Cheadle, UK). Microarray experiments were performed at Cambridge 69 
Genomic Services, University of Cambridge, using the HumanHT-12 v4 70 
Expression BeadChip (Illumina, Chesterford, UK) according to the 71 
manufacturer’s instructions. Briefly, 200ng of Total RNA underwent linear 72 
amplification using the Illumina TotalPrep RNA Amplification Kit (Life 73 
Technologies, Paisley, UK) following the manufacturer’s instructions. The 74 
concentration, purity and integrity of the resulting cRNA were measured by 75 
SpectroStar and Bioanalyser. Finally cRNA was hybridised to the HumanHT-76 
12 v4 BeadChip overnight followed by washing, staining and scanning using 77 
the Bead Array Reader (Illumina). The microarray data are available on 78 
ArrayExpress (Accession number: E-MTAB-4591). For reviewer access, 79 
please use the following login details Username: Reviewer_E-MTAB-4591 80 
Password: rtIImbi0 81 
Microarrays analysis 82 
Raw data was loaded into R using the lumi package from bioconductor (25) 83 
and divided into subsets according to the groups being compared; only the 84 
samples involved in a given comparison are used. Subsets were then filtered 85 
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to remove any non-expressed probes using the detection p-value from 1 
Illumina. Across all samples probes for which the intensity values were not 2 
statistically significantly different (p>0.01) from the negative controls were 3 
removed from the analysis. Following filtering the data was transformed using 4 
the Variance Stabilization Transformation (26) from lumi and then normalised 5 
to remove technical variation between arrays using quantile normalisation. 6 
Comparisons were performed using the limma package (27) with results 7 
corrected for multiple testing using False Discovery Rate (FDR) correction. 8 
Finally the quality of the data was assessed along with the correlations 9 
between samples within groups. 10 
Probes differentially expressed between HEP and ECOs representing the 11 
aggregate transcriptional “signature” of ECOs were selected for Euclidean 12 
hierarchical clustering using Perseus software (MaxQuant). Standard scores 13 
(z-scores) of the log2 normalized probe expression values across the different 14 
conditions were calculated and used for this analysis. 15 
Western Analysis 16 
Total protein was extracted with lysis buffer (50mM Tris pH 8, 150mM NaCl, 17 
0.1% SDS, 0.5% sodium deoxycholate, 1% Trition X-100 and protease and 18 
phosphatase inhibitors). Protein concentrations were determined by BCA 19 
Protein Assay Kit (Thermo Fisher Scientific) according to the manufacturer’s 20 
instructions. Samples were prepared for Western blot by adding 1x NuPAGE 21 
LDS Sample Buffer with 1% β-mercaptoethanol and incubated for 5 minutes 22 
at 95°C. Protein (25 μg) was separated by 4-12% NuPAGE Bis-Tris protein 23 
gels (Invitrogen) and transferred onto PVDF membranes (Bio-Rad). Proteins 24 
were detected by probing with antibodies specific to Phospho-β-catenin 25 
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(Ser33/37/Thr41) (Cell Signalling Technology), Active-β-catenin (Millipore), 1 
Total-β-catenin (R&D), α-tubulin (Sigma) followed by incubation with 2 
horseradish peroxidase anti-mouse, anti-goat or anti-rabbit secondary 3 
antibodies. Membranes were developed using Pierce ECL Western blotting 4 
substrate (Thermo Scientific) according to the manufacturer’s instructions. 5 
Rho Kinase activity analyses 6 
Rho Kinase activity was measured using a commercially available kit (Cell 7 
Biolabs, STA-416) according to the manufacturer’s instructions 8 
Flow cytometry analyses 9 
ECO organoids were harvested using Cell Recovery Solution (Corning) for 30 10 
minutes at 4oC, centrifuged at 444g for 4 minutes and dissociated to single 11 
cells using TrypLETM Express (Gibco).  The cells were subsequently fixed 12 
using 4% PFA for 20 minutes at 4oC. Cell staining and flow cytometry 13 
analyses were performed as previously described (9,28). 14 
Karyotyping 15 
ECO organoids were harvested using Cell Recovery Solution (Corning), 16 
dissociated to single cells as described above, plated in gelatin coated plates 17 
and cultured using William’s E medium with supplements. When the cells 18 
were sub-confluent, usually after 72hrs, the cultures were incubated for 3-4 19 
hours with William’s E medium with supplements containing 0.1μg/ml 20 
colcemid (Karyomax®, Gibco). The cells were then harvested using Trypsin-21 
EDTA (0.05%) (Gibco) for 4-5 minutes at 37oC, centrifuged at 344g for 5 22 
minutes and re-suspended in 5mls of KCl hypotonic solution (0.055M). The 23 
suspension was re-centrifuged at 344g for 5 minutes, 2 mls of a 3:1 100% 24 
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methanol:glacial acetic acid solution were added and slides were prepared as 1 
previously described (29) 2 
Comparative Genomic Hybridization analyses 3 
Genomic DNA was labeled using the BioPrime DNA Labeling Kit (Invitrogen), 4 
according to the manufacturer’s instructions and samples were hybridised to 5 
Agilent Sureprint G3 unrestricted CGH ISCA 8x60K human genome arrays 6 
following the manufacturer’s protocol, as previously described (30).  The data 7 
was analysed using the Agilent CytoGenomics Software. 8 
Rhodamine123 transport assay 9 
The Rhodamine 123 transport assay was performed as previously described 10 
(9) and images were acquired using a Zeiss LSM 700 confocal microscope. 11 
Fluorescence intensity was measured between the organoid interior and 12 
exterior and luminal fluorescence was normalized over the background of the 13 
extraluminal space. Each experiment was repeated in triplicate. Error bars 14 
represent SD. Mean fluorescence intensity comparisons were performed 15 
using a two sided student’s t-test. 16 
Cholyl-Lysyl-Fluorescein transport assay 17 
To achieve loading with Cholyl-Lysyl-Fluorescein (CLF, Corning 18 
Incorporated), ECO organoids were split in 5µM of CLF and incubated at 37oC 19 
for 30 minutes.  Images were acquired using a Zeiss LSM 700 confocal 20 
microscope and fluorescence intensity was measured between the organoid 21 
interior and exterior as described for the Rhodamine 123 transport assay. To 22 
demonstrate that the changes in CLF fluorescence intensity observed were 23 
secondary to active export of CLF from the organoid lumen, the experiment 24 
was repeated with 5µM of unconjucated Fluorescein Isothiocyanate (FITC) 25 
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(Sigma-Aldrich) as a control. Fluorescence intensity measurements were 1 
performed as described for the Rhodamine 123 transport assay. Each 2 
experiment was repeated in triplicate. Error bars represent SD. Mean 3 
fluorescence intensity comparisons were performed using a two sided 4 
student’s t-test. 5 
GGT activity 6 
GGT activity was measured in triplicate using the MaxDiscovery™ gamma-7 
Glutamyl Transferase (GGT) Enzymatic Assay Kit (Bioo scientific) based on 8 
the manufacturer’s instructions. Error bars represent SD. Mean absorbance 9 
was compared using a two sided student’s t-test. 10 
Alkaline Phosphatase staining 11 
Alkaline phosphatase was carried out using the BCIP/NBT Color 12 
Development Substrate (5-bromo-4-chloro-3-indolyl-phosphate/nitro blue 13 
tetrazolium) (Promega) according to the manufacturer’s instructions. 14 
Response to Secretin and Somatostatin 15 
Responses to secretin and somatostatin were assessed as previously 16 
described (9). 17 
Generation of ECOs expressing Green Fluorescent Protein 18 
EGFP expressing VSV-G pseudotyped, recombinant HIV-1 lentiviral particles 19 
were produced with an optimized second generation packaging system by 20 
transient co-transfection of three plasmids into HEK 293T cells (ATCC CRL-21 
11268). EGFP expression is under control of a core EF1α-promoter. All 22 
plasmids were a gift from Didier Trono and obtained from addgene (pWPT-23 
GFP #12255, psPAX2 #12260, pMD2.G, #12259). Viral infection of organoids 24 
was performed as previously described (31). Infected ECOs were expanded 25 
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for 2 passages, harvested as described above for flow cytometry analyses 1 
and cell sorting by flow cytometry for GFP positive cells was performed.  GFP 2 
expressing single cells were plated using our standard plating method and 3 
cultured in William’s E medium with supplements for 1-2 weeks until fully 4 
grown ECO organoids developed. 5 
Generation of ECO populated PGA scaffolds 6 
1mm thick PolyGlycolic Acid (PGA) scaffolds with a density of 50mg/cc were 7 
used for all experiments. Prior to seeding cells, the PGA scaffolds were pre-8 
treated with a 1M NaOH for 10-30 seconds washed 3 times, decontaminated 9 
in a 70% ethanol solution for 30 minutes and then air-dried for another 30 10 
minutes until all the ethanol had fully evaporated. All scaffolds were a gift from 11 
Dr Sanjay Sinha and obtained from Biomedical Structures (Biofelt). 12 
ECOs were harvested and dissociated to single cells as previously described 13 
for flow cytometry analyses. 5-10x106 cells were re-suspended in 100 μl of 14 
William’s E medium with supplements, seeded on a scaffold surface area of 15 
1cm2 and incubated at 37oC for 30-60 minutes to allow the cells to attach to 16 
the scaffold. The scaffolds were placed in wells of a 24-well plate and 17 
checked at regular intervals during this period to ensure the medium did not 18 
evaporate. If necessary, 10-20 μl of William’s E medium with supplements 19 
were added. After 1 hour, 2-3 mls of William’s E medium with supplements 20 
were added to the wells and the medium was changed twice weekly. 21 
Generation of densified collagen tubes 22 
Densified collagen tubes were prepared using a novel approach. A 3D printed 23 
chamber was fabricated, consisting of a funnel piece and a base plate. A 24 
250μm thick metallic wire was mounted into the base plate and fed through 25 
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the centre of the funnel. Absorbent paper towels were compacted between 1 
the two 3D printed parts, which were then screwed together. 5 mg mL-1 2 
collagen gel solution, loaded with cells, was poured into the funnel and gelled 3 
at 37ºC for 30 min. After that time, the screws were loosened and, by placing 4 
the 3D printed chambers at 37ºC for 2-4h, water was drawn out of the 5 
collagen gel. A cell-loaded densified collagen tube was thus formed with a 6 
250μm lumen and a wall thickness of 30-100 μm, determined by the duration 7 
of the drying phase. Upon removal from the chamber, the tube was trimmed 8 
for excess collagen and cut to the required length. 9 
Culture of Human Mammary Epithelial Cells (HMECs) 10 
HMECs and the required tissue culture consumables were purchased as a kit 11 
from Lonza (cat no. cat no. CC-2551B) and the cells were cultured according 12 
to the supplier’s instructions 13 
Animal experiments 14 
All animal experiments were performed in accordance with UK Home Office 15 
regulations. Immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice 16 
which lack B, T and NK lymphocytes (32) were bred in-house with food and 17 
water available ad libitum pre- and post-procedures. A mix of male and female 18 
animals were used, aged approximately 6-8 weeks. All the ECO-constructs 19 
used were populated with ECOs derived from the common bile duct. 20 
Generation of ExtraHepatic Biliary Injury mouse model 21 
To generate a model of extrahepatic biliary injury, midline laparotomy was 22 
performed and the gallbladder was first mobilized by dividing the ligamentous 23 
attachment connecting its fundus to the anterior abdominal wall under 24 
isoflurane general anesthesia. A longitudinal incision was then made along 25 
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2/3 of the length of the gallbladder, from the fundus towards Hartmann’s 1 
pouch (neck of gallbladder).  2 
Biliary reconstruction in EHBI mice 3 
To reconstruct the gallbladder, a scaffold section measuring approximately 1 x 4 
1 mm (seeded with ECOs or without ECOs in controls) was sutured as a 5 
‘patch’ to close the defect using 4 – 6 interrupted 10’0 non-absorbable nylon 6 
sutures under 40x magnification. The laparotomy was closed in two layers 7 
with continuous 5’0 absorbable Vicryl sutures. The animals were given 8 
buprenorphine (temgesic 0.1 mg/kg) analgesia as a bolus and observed every 9 
15 minutes in individual cages until fully recovered. 10 
8 animals underwent biliary reconstruction using an ECO-populated scaffold. 11 
All animals survived up to 104 days without complications and were culled 12 
electively for further analyses. Two control experiments were performed, 13 
where the animals underwent biliary reconstruction using acellular scaffolds. 14 
Both animals died within 24 hours from bile leak, therefore no further control 15 
experiments were performed to minimize animal discomfort. 16 
Bile duct replacement 17 
The native common bile duct was divided and a short segment excised. The 18 
populated densified collagen tube was anastomosed end-to-end, using 19 
interrupted 10’0 nylon sutures, between the divided proximal and distal 20 
common bile duct. A length of 5’0 nylon suture material (diameter 100 µm) 21 
was inserted into the collagen tube and fed into the proximal and distal 22 
common bile duct to ensure patency of the lumen during the anastomosis. 23 
After the anastomosis was complete, the 5’0 suture was pushed into the 24 
duodenum through the distal bile duct and was removed through an incision in 25 
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the duodenum, which was then closed with interrupted 10’0 nylon sutures. 1 
Lumen patency was assessed at the time of transplantation through light 2 
microscopy and cannulation of the lumen with a 5’0 non-absorbable suture. 3 
Transplantation was abandoned as futile in case of fully occluded tubes due 4 
to cell infiltration. These events were considered construct/tube failure rather 5 
than surgical complications and therefore were not censored in the survival 6 
analysis. 7 
Bile duct ligation 8 
C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, 9 
ME). The mice were housed and bred in a Minimal Disease Unit at the animal 10 
facility at Oslo University Hospital, Rikshospitalet, Oslo. All experiments were 11 
performed on male mice between 8 and 12 weeks of age. We performed a 12 
median laparotomy exposed the bile duct and ligated the common bile duct 13 
close to the junction of the hepatic bile ducts. Sham operated mice underwent 14 
the exact same procedure without ligation. Serum was harvested after 5 days. 15 
Alanine transaminase (ALT), aspartate transaminase (AST) and alkaline 16 
phosphatase (ALP) were measured in serum using an ADVIA 1800 (Siemens) 17 
at The Central Laboratory, Norwegian School of Veterinary Science. All 18 
animal experiments were approved by the Norwegian Food Safety Authority 19 
(project license no FOTS 8210/15) and all animals received human care in 20 
line with "Guide for the Care and Use of Laboratory Animals" (National 21 
Institutes of Health Publication, 8th Edition, 2011). 22 
Blood sample collection 23 
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Blood was taken using a 23g needles directly from the inferior vena cava 1 
under terminal anaesthesia at the time the animals were electively culled and 2 
transferred into 1.5ml Eppendorf tubes for further processing. 3 
Blood sample processing 4 
The blood samples were routinely processed by the University of Cambridge 5 
Core biochemical assay laboratory (CBAL). All of the sample analysis was 6 
performed on a Siemens Dimension EXL analyzer using reagents and assay 7 
protocols supplied by Siemens. 8 
Light microscopy imaging 9 
Light microscopy images of excised reconstructed gallbladders were acquired 10 
using a Leica MZFLIII fluorescence dissecting microscope. The images are 11 
representative of 5 animals. 12 
Cryosectioning and Histology 13 
Excised gallbladders were fixed in 4% PFA, immersed in sucrose solution 14 
overnight, mounted in optimal cutting temperature (OCT) compound and 15 
stored at -80°C until sectioning. Sections were cut to a thickness of 10µm 16 
using a cryostat microtome and mounted on microscopy slides for further 17 
analysis 18 
Haematoxylin and Eosin Staining 19 
H&E staining was performed using Sigma-Aldrich reagents according to the 20 
manufacturer’s instructions. Briefly, tissue sections were hydrated, treated 21 
with Meyer’s Haematoxylin solution for 5 minutes (Sigma-Aldrich), washed 22 
with warm tap water for 15 minutes, placed in distilled water for 30-60 23 
seconds and treated with eosin solution (Sigma-Aldrich) for 30-60 seconds. 24 
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The sections were subsequently dehydrated and mounted using the Eukitt® 1 
quick-hardening mounting medium (Sigma-Aldrich). Histology sections were 2 
reviewed by an independent histopathologist with a special interest in 3 
hepatobiliary histology (SD). 4 
TUNEL assay 5 
The TUNEL assay was performed using a commercially available kit (abcam, 6 
ab66110) according to the manufacturer’s instructions. 7 
Fluorescein Isothiocyanate (FITC) cholangiogram 8 
In situ FITC cholangiogram was performed in sacrificed animals after 9 
dissection of the gallbladder free from the adherent liver lobes, but before 10 
surgical interruption of the extrahepatic biliary tree. The distal bile duct was 11 
cannulated with a 23½ gauge needle and FITC injected retrogradely into the 12 
gallbladder and images taken under a fluorescent microscope. 13 
Magnetic resonance cholangiogram (MRCP) 14 
Magnetic resonance cholangiogram (MRCP) was performed after sacrifice of 15 
the animals. MRCP was performed at 4.7T using a Bruker BioSpec 47/40 16 
system. A rapid acquisition with relaxation enhancement sequence was used 17 
with an echo train length of 40 echoes at 9.5ms intervals, a repetition time of 18 
1000ms, field of view 5.84×4.18×4.18cm3 with a matrix of 256×180×180 19 
yielding an isotropic resolution of 230µm. The actively-decoupled four-channel 20 
mouse cardiac array provided by Bruker was used for imaging. 21 
For the second mouse imaged, for higher signal to noise ratio to give 22 
improved visualisation of the biliary ducts a two-dimensional sequence was 23 
used with slightly varied parameters (24 spaced echoes at 11ms intervals to 24 
give an effective echo time of 110ms; repetition time 5741ms; matrix size of 25 
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256×256; field of view of 4.33×5.35cm2 yielding a planar resolution of 1 
170×200µm2). Fifteen slices were acquired coronally through the liver and gall 2 
bladder with a thickness of 0.6mm. For this acquisition, a volume coil was 3 
used to reduce the impact of radiofrequency inhomogeneity. 4 
To examine the biliary ducts and gall bladder, images were prepared by 5 
maximum intensity projections. Structural imaging to rule out neoplastic 6 
growths was performed using a T1-weighted 3D FLASH (fast low-angle shot) 7 
sequence with a flip angle of 25°, repetition time of 14ms and an echo time of 8 
7ms. The matrix was 512×256×256 with a field of view of 5.12×2.56×2.56cm3 9 
for a final isotropic resolution of 100µm. 10 
The MRCP images were reviewed by 2 independent radiologists with a 11 
special interest in hepatobiliary radiology (EMG, SU). 12 
Statistical analyses 13 
All statistical analyses were performed using GraphPad Prism 6. For small 14 
sample sizes where descriptive statistics are not appropriate, individual data 15 
points were plotted. For comparison between 2 mean values a 2-sided 16 
student’s t-test was used to calculate statistical significance. The normal 17 
distribution of our values was confirmed using the D'Agostino & Pearson 18 
omnibus normality test where appropriate. Variance between samples was 19 
tested using the Brown-Forsythe test. For comparing multiple groups to a 20 
reference group one-way ANOVA with Dunnett correction for multiple 21 
comparisons was used between groups with equal variance, while the 22 
Kruskal-Wallis test with Dunn’s correction for multiple comparisons was 23 
applied for groups with unequal variance. Survival was compared using log-24 
rank (Mantel-Cox) tests. Where the number of replicates (n) is given this 25 
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refers to biological replicates or number of different animals unless otherwise 1 
stated. 2 
For animal experiments, initial group sizes were estimated based on previous 3 
study variance. No statistical methods were used to calculate sample size. No 4 
formal randomization method was used to assign animals to the experimental 5 
group. However; animals were randomly picked from a cage by a technician 6 
not involved in the study. No animals were excluded from the analysis. No 7 
blinding was used when reviewing radiology images or histopathology slides. 8 
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Figure Legends 1 
 2 
Figure 1 3 
Derivation and characterization of Extrahepatic Cholangiocyte Organoids 4 
(ECOs). (a) Schematic representation of the method used for the derivation of 5 
ECOs. (b) Photograph of a 24-well plate well containing ECO organoids under 6 
3D culture conditions. Scale bar: 1cm (c) Light microscopy image of ECO 7 
organoids. Scale bar: 1 mm (d) Transmitted electron microscopy picture of 8 
ECOs demonstrating the presence of cilia (black arrowhead). Scale bar: 9 
500nm (e) Quantitative real time PCR (QPCR) confirming the expression of 10 
biliary markers in Passage 1 (P1), Passage 10 (P10) and Passage 20 (P20) 11 
ECOs compared to freshly isolated Primary Cholangiocytes (PCs) and 12 
Embryonic Stem  (ES) cells used as a negative control, n=4 biological 13 
replicates. Center line, median; box, interquartile range (IQR); whiskers, range 14 
(minimum to maximum). Values are relative to the housekeeping gene 15 
Hydroxymethylbilane Synthase (HMBS) (f) Immunofluorescence (IF) analyses 16 
confirming the expression of biliary markers in ECO organoids. Scale bars: 17 
100 μm. Single channel and higher magnification images are provided in 18 
Supplementary Figure 6a. (g) Euclidian hierarchical clustering analysis 19 
comparing the transcriptome of primary cholangiocytes (Primary), passage 20 20 
ECOs (ECO), iPS-derived intrahepatic cholancgiocyte-like-cells (iChoLC), ES 21 
cells (ES) and hepatocytes (HEP). For each probe, standard scores (z-22 
scores) indicate the differential expression measured in number of standard 23 
deviations from the average level across all the samples. Clusters of genes 24 
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expressed in ECOs, primary cholangiocytes or both cell types are indicated. 1 
GO analyses for each cluster are provided in Supplementary Figure 7e. The 2 
data corresponds to biological triplicates. 3 
 4 
Figure 2 5 
Functional characterization of ECO organoids. (a) Fluorescence images 6 
demonstrating secretion of the MDR1 fluorescent substrate rhodamine 123 in 7 
the lumen of ECOs. Luminal accumulation of rhodamine is inhibited the MDR1 8 
inhibitor verapamil, confirming MDR1 activity. Scale bars: 100 μm. (b) 9 
Fluorescence intensity along the red line in (a). (c) Mean intraluminal 10 
fluorescence intensity normalized to background in freshly plated Primary 11 
Cholangiocytes (Rho PCs), Passage 20 ECOs (Rho P20) and P20 ECOs 12 
treated with verapamil (Ver). Error bars, Standard Deviation (SD); n=1565 13 
measurements in total. Asterisks (****) indicate statistical significance 14 
(P<0.001, Kruskal-Wallis test with Dunn’s correction for multiple comparisons) 15 
(d) Luminal extrusion of the fluorescent bile acid CLF compared to controls 16 
loaded with Fluorescein Isothiocyanate (FITC), confirming active bile acid 17 
transfer. Scale bars: 100 μm. (e) Fluorescence intensity along the red line in 18 
(d). (f) Mean intra-luminal fluorescence intensity normalized over background, 19 
n=1947 total measurements. Error bars, SD; asterisks as in (c). (g) ALP 20 
staining of ECOs. Scale bars: Light microscopy: 500μm, Whole well images: 21 
1cm. (h) Mean GGT activity of P20 ECOs vs. PCs; error bars, SD; n=3, 22 
asterisks as in (c). (i,j)  Mean diameter measurements (i) and live images (j) 23 
of ECOs treated with secretin or secretin and somatostatin, n=8. Error bars, 24 
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SD; ***P<0.001; #P>0.05 (Kruskal-Wallis test with Dunn’s correction for 1 
multiple comparisons). (a-j) Data representative of 3 different experiments. 2 
 3 
Figure 3 4 
Biliary reconstruction in an extrahepatic biliary injury (EHBI) mouse model 5 
using ECOs. (a) Schematic representation of the method used for biliary 6 
reconstruction. (b) Kaplan–Meier survival analysis, demonstrating rescue of 7 
EHBI mice following biliary reconstruction with ECO-populated scaffolds. 8 
**P<0.01 (log-rank test). (c) Images of gallbladders reconstructed with 9 
acellular PGA scaffolds (scaffold only), PGA scaffolds populated with ECOs 10 
(transplanted) and native not reconstructed gallbladder controls (not 11 
transplanted), demonstrating full reconstruction with ECO populated scaffolds. 12 
CD: cystic duct, CBD: common bile duct, CHD: common hepatic duct, F: 13 
fundus, A: anterior surface, P: posterior surface. Scale bars: 500μm. (d) H&E 14 
staining demonstrating physiological architecture of the reconstructed 15 
gallbladders. L: lumen. Scale bars: 100μm (e) IF analyses demonstrating the 16 
presence of GFP-positive ECOs expressing biliary markers in the 17 
reconstructed gallbladders. L: lumen Scale bars: 100 μm. Higher 18 
magnification images are provided in supplementary figure 14 (f,g) FITC 19 
cholangiogram (n=1) (f) and Magnetic Resonance Cholangio-20 
Pancreatography (MRCP) images (n=2) (g) of reconstructed (transplanted) 21 
vs. native control (not transplanted) gallbladders (GB) demonstrating a patent 22 
lumen and unobstructed communication with the rest of the biliary tree. Scale 23 
bars: 1mm 24 
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 1 
Figure 4 2 
Bile duct replacement using ECO-populated densified collagen tubes. (a) 3 
Schematic representation of the method used. (b) Postmortem images of 4 
mice receiving ECO-populated collagen tubes (ECOs) vs. mice receiving 5 
fibroblast-populated tubes (fibroblasts). Bile flow results in yellow 6 
pigmentation of ECO-tubes. The white color of the fibroblast conduit 7 
combined with a dilated bile-filled (yellow color) proximal bile duct (PDB) 8 
suggests luminal occlusion, resulting in bile leak (yellow peritoneal 9 
pigmentation; white dashed line). SC: Collagen tubes/scaffolds; DBD: Distal 10 
Bile duct; scale bars 500μm. (c) Images of a thin walled construct resembling 11 
the native bile duct in animals receiving ECO-populated tubes vs. a thickened 12 
construct with no distinguishable lumen in animals receiving fibroblast tubes. 13 
Scale bars 500μm. (d) QPCR using human-specific primers confirming the 14 
expression of biliary markers by transplanted ECO-populated tubes (ECOs in 15 
vivo) compared to cultured ECOs (ECOs in vitro) and mouse biliary tissue 16 
used as a negative control, n=4 replicates. Center line, median; box, 17 
interquartile range (IQR); whiskers, range (minimum to maximum). Values are 18 
relative to HMBS expression. (e) H&E staining demonstrating the presence of 19 
a biliary epithelium and a patent lumen in ECO-tubes but not fibroblast 20 
constructs. Scale bars 100μm. (f) IF analyses demonstrating a GFP+/ CK19+ 21 
epithelium lining the lumen of ECO-constructs, vs. obliteration of the lumen by 22 
fibroblasts in fibroblast constructs. Scale bars 100μm. (g) FITC 23 
cholangiogram, demonstrating lumen patency in ECO-tubes vs. lumen 24 
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occlusion in fibro-constructs. Scale bars: 500μm (h) ALP activity is observed 1 
only in ECO-tubes, but not in fibroblast constructs. Scale bars: 500μm 2 
a 
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Supplementary Note 1 
Supplementary Results 2 
To assess the potential of ECOs for tissue engineering, we first interrogated their 3 
capacity for populating Polyglycolic Acid (PGA) biodegradable scaffolds commonly 4 
used to provide the structural and mechanical support required for tissue 5 
reconstruction (1). Indeed, PGA is one of the most widely used synthetic polymers 6 
since it does not induce inflammatory responses in the surrounding tissue; it is 7 
biodegradable; and it is more flexible and easier to process compared to natural 8 
polymers such as collagen (2). To facilitate tracking of the cells, ECOs expressing 9 
Green Fluorescent Protein (GFP) were generated through viral transduction 10 
(Supplementary Fig. 10a-10b). The resulting cells were seeded on PGA scaffolds, 11 
attached to the PGA fibers after 24-48 hours and continued to grow for 4 weeks until 12 
the scaffold was confluent (Supplementary Fig 11a-11d). Primary cholangiocytes 13 
plated in 2D conditions demonstrated limited expansion potential and failed to reach 14 
confluency when seeded on the scaffolds (Supplementary Fig 12a-b), suggesting 15 
that the proliferative capacity of ECOs is crucial for successful scaffold colonization. 16 
The populated PGA scaffolds (Supplementary Fig 11b-11c), could easily be handled 17 
with forceps and divided into smaller pieces with a surgical blade. Furthermore, the 18 
cells populating the scaffolds retained expression of biliary markers such as CK7 and 19 
CK19 (Supplementary Fig 11e-11f), demonstrated no evidence of EMT 20 
(Supplementary Fig. 11e, 11g) and maintained their functional properties including 21 
ALP and GGT activity (Supplementary Figure 11h-11i). Therefore, ECOs can 22 
successfully populate PGA scaffolds, while maintaining their functionality and marker 23 
expression. 24 
 
 
2 
 
We then focused on the generation of a tubular ECO-populated scaffold, which could 1 
be used in the context of bile duct replacement surgery. The internal diameter of the 2 
mouse CBD is approximately 100μm with a wall thickness of less than 50μm, which 3 
precluded the use of a PGA scaffold due to mechanical properties. Instead, we 4 
generated densified collagen tubular scaffolds (Supplementary Fig 15a-15b) which 5 
were populated with GFP-expressing ECOs (supplementary Fig 15c-15e). The use 6 
of densified collagen enabled the generation of constructs with an external diameter 7 
ranging from 250 to 600μm and adequate strength to maintain a patent lumen 8 
(Supplementary Fig 15d). Importantly, the cells populating the collagen scaffolds 9 
maintained expression of biliary markers such as CK19, CK7, HNF1b, Sox9 and 10 
CFTR (Supplementary Fig 15f-15g) and exhibited GGT and ALP enzymatic activity 11 
(Supplementary Fig 15h-15i). Primary epithelial cells of different origin (human 12 
mammary epithelial cells; HMEC) failed to survive and adequately populate densified 13 
collagen tubes under the same conditions (Supplementary Fig. 16a). Moreover, 14 
plated HMECs failed to survive in a 10% (vol/vol) bile solution compared to ECOs 15 
(Supplementary Fig. 16b), further confirming that ECOs constitute the only cell type 16 
capable of generating bile resistant bio-engineered bile ducts. Collectively, these 17 
results demonstrate the capacity of ECOs for populating tubular densified collagen 18 
scaffolds without losing their original characteristics.  19 
 20 
Supplementary discussion 21 
Our system provides proof-of-principle for the application of primary cells in 22 
regenerative medicine; however, the use of stem cells has been suggested as an 23 
alternative for cell based therapy. Although we have recently established a system 24 
 
 
3 
 
for the generation of stem cell-derived cholangiocyte-like cells (CLCs) (3), there are 1 
significant differences between ECOs and CLCs that render ECOs better suited to 2 
regenerative therapies for extrahepatic biliary injury. CLCs correspond to intrahepatic 3 
cholangiocytes, while ECOs represent extrahepatic biliary epithelium. These two cell 4 
types are distinct in terms of embryological origin and disease involvement (4). 5 
Furthermore, CLCs still express fetal markers and therefore are more immature 6 
compared to ECOs derived from primary cells (3). Therefore, CLCs may require a 7 
period of adjustment and further maturation in vivo, while mature, functional cells, 8 
such as ECOs, are required for coping with biliary injury in the acute setting. Finally, 9 
although hIPSCs provide a very good source of cells capable of generating almost 10 
any tissue, fully differentiated CLCs cannot be expanded; initial derivation/ 11 
characterization of hIPSC lines remains time consuming; while variability in capacity 12 
of differentiation still constitutes a challenge. ECOs can be derived in less than 24 13 
hours with a very high efficiency and can be expanded for multiple passages without 14 
losing their original characteristics. Consequently, ECOs are comparable to CLCs in 15 
terms of scalability, while their mature phenotype provides a unique advantage for 16 
regenerative medicine applications in the context of tissue repair. 17 
 18 
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Supplementary Figure 1  1 
Screening for optimal conditions for the isolation and propagation of extra-hepatic 2 
cholangiocytes (a) Mean viability ratio following isolation of primary cholangiocytes 3 
with different methods. C+D: Collagenase + Dispase. Error bars, SD; n=3. Asterisks 4 
represent statistically significant differences in viability ratio between mechanical 5 
dissociation and other isolation methods; ***P<0.001, ****P<0.0001; one-way 6 
ANOVA with Dunnett correction for multiple comparisons (b) Mean number of 7 
resulting cells following 7 days of culture with various growth factors. E: Epidermal 8 
Growth Factor, R: R-spondin, D: DKK-1, IL6: Interleukin-6, HGF: Hepatocyte Growth 9 
Factor, VEGF: Vascular Endothelial Growth Factor, FBS: Foetal Bovine serum, F2: 10 
Fibroblast Growth Factor (FGF) 2, F7: FGF-7, F10: FGF-10, A: Activin-A, SB: Activin 11 
inhibitor SB-431542. Error bars, SD; n=3. Asterisks represent statistically significant 12 
differences in the number of resulting cells between E+R+D and other culture 13 
conditions; ****P<0.0001; one-way ANOVA with Dunnett correction for multiple 14 
comparisons (c) Representative live images of freshly isolated primary 15 
cholangiocytes grown under different culture conditions for 7 days. EGF: Epidermal 16 
Growth Factor. Scale bars: 500 μm. (d) Western blot analyses demonstrating 17 
increased levels of phosphorylated β-catenin in ECOs treated with R-spondin and 18 
DKK vs. R-spondin alone or R-spondin and the GSK-3  inhibitor CHIR 99021 (CHIR), 19 
used as a positive control. (e) Quantification of the western blot demonstrated in 20 
panel (d). (f) ECOs treated with R-spondin and DKK exhibit increased Rho Kinase 21 
activity, consistent with non-canonical Wnt signalling/ PCP pathway activation. Error 22 
bars: SD; ****P<0.0001; one way anova with Dunnett correction for multiple 23 
comparisons; n=3; Y-27632: Rho Kinase inhibitor Y-27632. 24 
 25 
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Supplementary Figure 2 1 
ECOs represent a highly homogeneous population of epithelial CK19+/CK7+ cells, 2 
with minimal mesenchymal contamination. Flow cytometry analyses demonstrating 3 
the expression of the biliary markers CK7 and CK19 but not the mesenchymal 4 
marker vimentin (VIM) in freshly isolated primary cholangiocytes (Primary) and 5 
Passage 20 (P20) ECOs, n=3. Fibroblasts are used as a positive control for 6 
mesenchymal markers. 7 
 8 
Supplementary Figure 3 9 
Characterization of ECO lines derived from the gallbladder and common bile duct 10 
brushings. (a) Schematic representation of the method for the derivation of ECOs 11 
from the gallbladder. (b) Schematic representation of the method for the derivation of 12 
ECOs from common bile duct brushings. (c) Quantitive real time PCR (QPCR) 13 
confirming the expression of biliary markers in Passage 20 (P20) organoids of 2 14 
ECO lines derived from common bile duct brushings (ECO_BR) and the gallbladder 15 
(ECO_GB). Freshly isolated cholangiocytes (Primary) are used as a positive control, 16 
n=4 biological replicates. Center line, median; box, interquartile range (IQR); 17 
whiskers, range (minimum to maximum). Values are relative to the housekeeping 18 
gene Hydroxymethylbilane Synthase (HMBS). (d) Immunofluorescence (IF) analyses 19 
confirming the expression of biliary markers in P20 ECO_BR and ECO_GB 20 
organoids. Scale bars: 100 μm. (e) ALP staining of P20 ECO_BR and ECO_GB 21 
organoids. Scale bars: 500μm. (f) Mean GGT activity of P20 ECO_BR and ECO_GB 22 
vs. primary cholangiocytes; n=3; error bars, SD. These data are complementary to 23 
the data shown in Figures 1 and 2.  24 
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 1 
Supplementary Figure 4 2 
Genetic stability of ECOs following long-term in vitro culture for 20 passages. (a) 3 
Growth curves of 3 different ECO lines cultured in vitro for 20 passages. (b) Normal 4 
Karyotype of ECOs at P20; n=3. (c) Comparative Genomic Hybridization analyses 5 
comparing ECOs at Passage 1 (red) and P20 (blue), demonstrating genomic stability 6 
in vitro; n=3. 7 
 8 
Supplementary Figure 5 9 
ECOs exhibit ultra-structural features characteristic of cholangiocytes. Transmission 10 
electron microscopy image demonstrating the presence of microvilli (white 11 
arrowheads) and tight junctions (black arrowheads) in passage 20 ECO cells. Scale 12 
bar: 2μm. 13 
 14 
Supplementary Figure 6 15 
ECOs express markers biliary markers. (a-b) Single channel (a) and high 16 
magnification (b) images of the IF analyses demonstrated in Figure 1f demonstrating 17 
the expression of biliary markers by ECOs. Scale bars: 100μm. These data are 18 
complementary to the data shown in Figure 1. 19 
 20 
Supplementary Figure 7 21 
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ECOs do not express markers of other lineages. (a) IF images demonstrating the 1 
lack of expression of stem cell markers or markers of other lineages (liver, pancreas) 2 
by ECOs. Scale bars: 100μm (b) IF images demonstrating appropriate positive 3 
controls expressing the markers demonstrated in (a). (c) QPCR analyses 4 
demonstrating the lack of expression of stem cell markers or markers of other 5 
lineages (liver, pancreas) by ECOs. Stel, activated stellate cells; Fibro, fibroblasts; 6 
HEP, primary human freshly plated hepatocytes; Panc, primary human pancreatic 7 
cells; ES, embryonic stem cells; HB, hIPSC-derived hepatoblasts; SC, ECO 8 
populated scaffolds; Int. Org., Intestinal Organoids; n=4 biological replicates; n=3 9 
biological replicates for POU5F1, NANOG, PROM1. Center line, median; box, 10 
interquartile range (IQR); whiskers, range (minimum to maximum). Values are 11 
relative to the housekeeping gene Hydroxymethylbilane Synthase (HMBS). 12 
 13 
Supplementary Figure 8 14 
Transcriptomic profile analyses of ECOs. (a) Euclidean hierarchical clustering 15 
analysis comparing the transcriptome of ECOs across multiple passages (P1, P10, 16 
P20) and Embryonic Stem (ES) cells used as a negative control, focusing on genes 17 
that define the transcriptional signature of ECOs (4513 genes differentially 18 
expressed between ECOs and ES cells). For each probe, standard scores (z-scores) 19 
indicate the differential expression measured in number of standard deviations from 20 
the average level across all the samples, n=3. (b) Heatmap showing the Pearson 21 
correlation coefficient (r) of the global gene expression between ECOs across 22 
multiple passages (P1, P10, P20), freshly isolated primary cholangiocytes (PCs), 23 
hIPSC-derived intrahepatic Cholangiocyte Like Cells (iChoLC), primary hepatocytes 24 
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(HEPs) and ES used as a negative control, n=3. The analysis was performed 1 
focusing on all probes detected in all 3 biological replicates. (c) Heatmap showing 2 
the expression of representative biliary, hepatic and stem cell markers between 3 
passage 20 ECOs (ECOs), PCs, HEPs and ES cells; n=3; z-scores as in (a). (c) 4 
Principal Component Analysis (PCA) between ECOs, PCs, iChoLC, HEPs and ES 5 
cells, n=3. The analysis was performed using all probes detected in all 3 replicates. 6 
ECOs cluster closely with primary cholangiocytes for component 1 accounting for 7 
41% of total variability. (d) Gene ontology (GO) analyses focusing on the genes 8 
differentially expressed between PCs and ECOs in Figure 1g; n=3. Characteristic 9 
GO terms from each cluster are provided (P<0.05). Terms associated with the biliary 10 
epithelium are identified only in the common cluster. 11 
 12 
Supplementary Figure 9 13 
ECOs injected under the kidney capsule of immune compromised mice form tubular 14 
structures expressing biliary markers, but do not demonstrate spontaneous 15 
differentiation in other lineages. (a) Schematic representation of the method used for 16 
the injection of ECOs. (b) Image of an excised kidney transplanted with ECOs; scale 17 
bar: 500μm. (c) Cross-section of a transplanted kidney demonstrating the formation 18 
of tubular structures; scale bar: 500μm. (d) IF images demonstrating the formation of 19 
tubular structures by the engrafted cells expressing the biliary marker CK7 and a 20 
human-specific Ku80 epitope, but not expressing stem cell markers or markers of 21 
other lineages (liver, pancreas). Scale bars: 100μm. 22 
 23 
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Supplementary Figure 10 1 
Generation of ECOs expressing Green Fluorescent Protein (GFP). (a) Flow 2 
cytometry analyses demonstrating the generation of a homogeneous population of 3 
GFP-ECOs following lentiviral transduction and flow sorting. (b) Confocal microscopy 4 
images demonstrating the generation of fully grown GFP-ECO organoids from a 5 
single GFP-expressing cell. Scale bars: 100 μm. Images are representative. 6 
 7 
Supplementary Figure 11 8 
ECOs dissociated to single cells (ECO-SCs) can populate biodegradable PGA 9 
scaffolds. (a,b) Photographs of a PGA scaffold before (a) and after (b) treatment with 10 
ECOs. Scale bars: 1cm. (c) Light microscopy images of a PGA scaffold populated 11 
with ECO-SCs. Red arrowheads: Fully populated scaffold; black arrowheads: cells 12 
recruiting new PGA fibers; white arrowheads: PGA fibers. Scale bars: 100μm. (d) 13 
Confocal microscopy images demonstrating cell expansion at different time-points 14 
after seeding of GFP-positive ECO-SCs on a PGA scaffold. White lines indicate the 15 
position of PGA fibers. Scale bars: 100μm. (e) IF demonstrating the expression of 16 
biliary markers and lack of EMT markers in ECO-SCs seeded on PGA scaffolds. 17 
Scale bars: 50μm (f) QPCR analyses demonstrating the expression of biliary 18 
markers in ECOs before (ECOs) and after (scaffold) seeding on PGA scaffolds, n=4 19 
biological replicates. Center line, median; box, interquartile range (IQR); whiskers, 20 
range (minimum to maximum). Values are relative to the housekeeping gene 21 
Hydroxymethylbilane Synthase (HMBS). (g) Ratio of CK7+/CK19+ and 22 
CK19+/Vimentin (VIM)+ cells in randomly selected IF images similar to the image 23 
shown in (e); n=6. (h) Mean GGT activity of ECO-SCs populating a PGA scaffold, 24 
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n=4. Error bars represent SD. ****P<0.001 (two-tailed t-test). (i) ALP staining of PGA 1 
scaffolds populated by ECO-SCs. Scale bars: 500μm. 2 
 3 
Supplementary Figure 12 4 
2D plated cholangiocytes fail to populate PGA scaffolds. (a) Growth curves of 5 
primary cholangiocytes plated as monolayer (2D) vs. primary cholangiocytes grown 6 
as ECOs (ECO), demonstrating that 2D cholangiocytes stop proliferating after a few 7 
passages. Starting from the same number of cells (5x105) 2D cholangiocytes fail to 8 
provide the number of cells required to seed a PGA scaffold (107 cells). (b) 9 
Brightfield images demonstrating that 2D cholangiocytes fail to expand and populate 10 
PGA scaffolds and remain limited to the site of injection. A brightfield image of a 11 
scaffold populated by ECOs dissociated to single cells (ECO-SC) is provided as a 12 
positive control. The scaffold was seeded with same number of cells and cultured for 13 
the same period of time as the 2D cholangiocyte scaffold. Scale bars: 100μm. 14 
 15 
Supplementary Figure 13 16 
Fibroblast-populated scaffolds fail to reconstruct the gallbladder following 17 
transplantation in EHBI mice. (a) Flow cytometry analyses demonstrating the 18 
generation of a homogeneous population of GFP-expressing Fibroblasts (GFP-Fibro) 19 
following lentiviral transduction. (b) IF images demonstrating the expression of GFP 20 
in fibroblasts following lentiviral transduction. Scale bars: 100μm. (c, d) Brightfied (c) 21 
and confocal microscopy (d) images demonstrating the generation of fibroblast 22 
populated PGA scaffolds. Scale bars: 100μm. (e,f) Postmortem images of 23 
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transplanted EHBI mice demonstrating failure to reconstruct the gallbladder with 1 
fibroblast-populated scaffolds. The site of reconstruction can only be identified by the 2 
presence of non-absorbable sutures (white arrowheads). Scale bars: 1mm. (g) 3 
Image of a gallbladder transplanted with a fibroblast-populated scaffold 4 
demonstrating failure to reconstruct the organ, abnormal morphology more 5 
consistent with a fibrotic mass and lack of a bile filled lumen. Scale bars: 1mm. (h) 6 
T2 phase Magnetic Resonance Images (MRI; axial plane) demonstrating the 7 
absence of a bile filled lumen in a gallbladder transplanted with a fibroblast 8 
populated scaffold. The white signal consistent with bile is identified up to the cystic 9 
duct but not at the site of the transplanted gallbladder. (i) H&E images demonstrating 10 
replacement of the gallbladder epithelium by fibroblasts and obliteration of the 11 
gallbladder lumen. (j) IF analyses demonstrating the abscence of GFP-expressing 12 
cells in the transplanted gallbladders, the lack of epithelial markers and the presence 13 
of connective tissue markers, Scale bars: 100μm.  14 
 15 
Supplementary Figure 14 16 
Characterization of ECO-reconstructed gallbladders in extrahepatic biliary injury 17 
(EHBI) mice. (a) Postmortem images of mice receiving acellular PGA scaffolds 18 
(scaffold only), healthy control mice (not transplanted) and mice receiving ECO-19 
populated PGA scaffolds (transplanted). The yellow pigmentation of the peritoneal 20 
cavity (top, white dashed line) and seminal vesicles (bottom, black dashed line) is 21 
consistent with bile leak in the ‘scaffold only’ group. Scale bars: 5mm (b) Post 22 
mortem images demonstrating the reconstructed gallbladders in situ (n=3). Black 23 
arrows: sutures; L: liver; scale bars: 1mm. (c) IF images of the transplanted 24 
 
 
13 
 
scaffolds, corresponding to figure 3e, demonstrating GFP-positive cells expressing 1 
human (Ku80) and biliary markers (CK19, CK7, CFTR) integrated in the 2 
reconstructed biliary epithelium; the presence of mouse stromal cells expressing 3 
vimentin and mouse endothelial cells expressing CD31; and the presence of GFP+, 4 
CK19-, Vimentin+ cells integrated in connective tissue of the reconstructed organ. 5 
Scale bars: 100μm. (d) QPCR analyses using human-specific primers confirming 6 
expression of biliary markers by transplanted ECO-populated scaffolds (ECOs in 7 
vivo) compared ECOs in vitro and mouse gallbladder used as a negative control, n=4 8 
replicates. Center line, median; box, interquartile range (IQR); whiskers, range 9 
(minimum to maximum). Values relative to HMBS expression. (e) Ratio of 10 
CK19+/CK7+, CK19+/GFP+ and Vimentin (VIM)/GFP+ cells  quantified in randomly 11 
selected sections of transplanted ECO-populated scaffolds; n=18. (f) T1&T2 vs. T2 12 
phase Magnetic Resonance Images (MRI; axial plane) demonstrating bile in the 13 
lumen of a reconstructed gallbladder (white signal) and a patent cystic duct relative 14 
to the surrounding liver (n=2). GB: Gallbladder; CD: Cystic Duct; L: Liver 15 
parenchyma. 16 
 17 
Supplementary Figure 15 18 
ECOs can populate densified collagen tubular scaffolds. (a) Schematic 19 
representation of the method used. (b) Image of a densified collagen construct prior 20 
to tube excision. Scale bar, 500μm. (c) Maximum intensity projection image 21 
demonstrating a GFP+ ECO-populated tube after its generation. Scale bar; 10μm (d) 22 
Confocal microscopy image demonstrating lumen patency of an ECO-populated 23 
collagen tube. Scale bar; 10μm. (e) Images of a near confluent GFP+ ECO-tube. 24 
Scale bar; 100μm. (f) IF analyses demonstrating the expression of biliary markers by 25 
 
 
14 
 
ECOs following the generation of ECO-tubes. Scale bar; 100μm. (g) QPCR analyses 1 
demonstrating the expression of biliary markers before (ECOs) and after (Scaffold) 2 
the generation of ECO-populated collagen tubes. ES cells are used as a negative 3 
control, n=4 replicates. Center line, median; box, interquartile range (IQR); whiskers, 4 
range (minimum to maximum). Values are relative to HMBS expression. (h, i) ECO-5 
tubes exhibit ALP (h) and GGT (i) activity. Scale bars, 500μm; MEFs, Mouse 6 
Embryonic feeders used as negative control; Scaffold, ECO-populated, densified 7 
collagen tubes; error bars, SD; n=3. 8 
 9 
Supplementary Figure 16 10 
Primary human mammary epithelial cells (HMECs) lack the capacity to adequately 11 
populate densified collagen scaffolds or survive in the environment of primary 12 
cholangiocytes. (a) Light microscopy images demonstrating failure of HMECs survive 13 
and adequately populate collagen tubular scaffolds. Scale bar: 100μm. (b) Flow 14 
cytometry analysis demonstrating survival of ECOs vs. plated HMECs following 15 
exposure to a 10% (vol/vol) bile solution. 16 
 17 
Supplementary Figure 17 18 
Survival analysis and characterization of ECO-populated densified collagen tubes. 19 
(a) H&E staining demonstrating the presence of a biliary epithelium and a patent 20 
lumen in ECO-tubes. The images are complementary to Figure 4e (b) IF analyses 21 
demonstrating the expression of human specific (Ku80), biliary (CK19, CK7, CFTR), 22 
stromal (Vimentin, VIM) and vascular (CD31) markers in transplanted bio-tubes 23 
populated with GFP+ ECOs. Apoptosis (TUNEL) and proliferation (Ki67) markers are 24 
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also demonstrated. Scale bars; 100μm. (c) IF images following TUNEL staining of 1 
transplanted fibroblast-populated collagen tubes, demonstrating increased cell 2 
death. Scale bars: 100μm. (d) Kaplan–Meier survival analysis demonstrating a 3 
survival benefit in NSG mice following biliary reconstruction with ECO-populated 4 
densified collagen tubes vs. fibroblast-populated densified collagen tube controls and 5 
untreated controls. ****P<0.0001 (log-rank test). (e) Liver function tests of untreated 6 
control animals (CTRL) vs. animals transplanted with ECO-populated tubes (ECOs) 7 
and Bile Duct Ligation (BDL) animals used as a positive control, demonstrating 8 
levels of serum cholestasis markers comparable to untreated controls following long-9 
term transplantation (n=5, 31 days; n=1, 27 days). Error bars, SD; ALP, Bilirubin 10 
(Bili), one-way ANOVA with Dunnett correction for multiple comparisons; Alanine 11 
aminotransferase (ALT), Kruskal-Wallis test; CTRL, n=11; ECOs, n=6; BDL, n=5. 12 
**P<0.01, ****P<0.0001, #P<0.05 (not statistically significant difference). (f) T2 phase 13 
Magnetic Resonance Images (MRI; coronal plane) 1 month following transplantation 14 
demonstrating bile in the lumen of a reconstructed bile duct (white signal) and a 15 
patent construct lumen (n=2). SC: ECO-populated collagen tubular scaffold; L: Liver 16 
parenchyma.  17 
 18 
Supplementary Video 1 19 
Magnetic Resonance Cholangio-Pancreatography (MRCP, sagital plane) of an 20 
Extrahepatic Biliary Injury (EHBI) mouse 104 days following biliary reconstruction 21 
with an ECO-populated scaffold. The T2 weighed image sequence demonstrates the 22 
presence of bile in the lumen of a reconstructed gallbladder (high intensity white 23 
signal) and a patent cystic duct. The surrounding tissues are characterized by low 24 
intensity signal and appear dark. To assess the anatomy of the surrounding organs 25 
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please refer to supplementary video 2 for a T1 weighed Magnetic Resonance 1 
Imaging sequence. 2 
 3 
Supplementary Video 2 4 
T1 weighed Magnetic Resonance Imaging (MRI) (coronal plane) of an Extrahepatic 5 
Biliary Injury (EHBI) mouse 104 days following biliary reconstruction with an ECO-6 
populated scaffold. This image sequence is optimal for demonstrating the anatomy 7 
of the tissue surrounding the reconstructed gallbladder and biliary tree. However, 8 
water, water-rich tissues and bile are characterized by low intensity signal, appear 9 
dark and may be difficult to identify 10 
 11 
Supplementary video 3 12 
Time lapse images demonstrating the generation of a fully grown organoid from a 13 
single cell. 14 
 15 
  16 
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Supplementary table 1 1 
Donor demographics, corresponding to 8 different ECO lines. DCD: Donation after 2 
Circulatory Death, DBD: Donation after Brain Death, F: Female, M: male, CBD: 3 
Common Bile Duct, GB: Gallbladder, BR: CBD Brushings 4 
 5 
Donor type Blood Group Age (years) Gender Site 
DCD O- 33 F CBD 
DBD O+ 56 F CBD 
DCD A- 77 M CBD 
DBD O+ 57 M CBD, GB 
DCD O- 44 M CBD, GB 
DCD O+ 48 M CBD 
DBD A+ 36 M BR 
DBD B+ 48 F BR 
 6 
 7 
 8 
Supplementary table 2 9 
Microarray gene expression data corresponding to the heat map in Figure 1g  10 
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Supplementary Table 3: List of antibodies used 1 
 2 
 3 
4 
Target protein  Dilution  Company  Cat Number 
CYTOKERATIN 19 1:100  ABCAM ab7754 
CYTOKERATIN 19 (KRT19) 1:50 DSHB TROMA-III 
SOX9 H-90  1:100  SANTA CRUZ sc-20095 
HNF1B (c-20) 1:100  SANTA CRUZ sc-7411 
CYTOKERATIN 7 (RCK105) 1:100 ABCAM ab9021 
CYTOKERATIN 7 1:100 ABCAM ab68459 
CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE 
REGULATOR (CFTR) 
1:100 SANTA CRUZ sc-10747 
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT) 1:100 ABCAM ab55138 
SOMATOSTATIN RECEPTOR 2 1:100 ABCAM ab134152 
SECRETIN RECEPTOR (C-20) 1:100 SANTA CRUZ sc-26633 
SECRETIN RECEPTOR 1:100 ABCAM ab85565 
ASBT (C14) 1:100 SANTA CRUZ sc-27493 
STEM101 HUMAN KU80 CELL NUCLEUS MARKER 1:100 STEM CELLS INC. Y40400 
ALEXA FLUOR DONKEY ANTI-Rabbit 568 1:1000 INVITROGEN A10042 
ALEXA FLUOR DONKEY ANTI-Rabbit 488 1:1000 INVITROGEN A21206 
ALEXA FLUOR DONKEY ANTI-Rabbit 647 1:1000 INVITROGEN A31573 
ALEXA FLUOR DONKEY ANTI-goat 568 1:1000 INVITROGEN A11057 
ALEXA FLUOR DONKEY ANTI-goat 488 1:1000 INVITROGEN A11055 
ALEXA FLUOR DONKEY ANTI-goat 647 1:1000 INVITROGEN A21447 
ALEXA FLUOR DONKEY ANTI-mouse 568 1:1000 INVITROGEN A10037 
ALEXA FLUOR DONKEY ANTI-mouse 488 1:1000 INVITROGEN A21202 
ALEXA FLUOR DONKEY ANTI-mouse 647 1:1000 INVITROGEN A31571 
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Supplementary table 4: List of primers used 1 
 2 
Gene  Primer sequence (5’ à 3’)  Gene  Primer sequence (5’ à 3’)  
HNF1B  F  TCACAGATACCAGCAGCATCAGT  CK7 F  GATTGCTGGCCTTCGGGGT 
   R  GGGCATCACCAGGCTTGTA  
 
R  TCATCACAGAGATATTCACGGCTC 
PBGD  F  GGAGCCATGTCTGGTAACGG  GGT F  GTGAGAGCAGTTGGCTGTGC 
 
R  CCACGCGAATCACTCTCATCT  
 
R  GTTGAACTCTGCTGTGGGGC 
SOX9 
 
Hs_SOX9_1_SG QuantiTect Primer Assay  CFTR F  AGTTGCAGATGAGGTTGGGC 
  
(Quiagen, Cat Number: QT00001498) 
 
R  AAAGAGCTTCACCCTGTCGG 
CK19 F  ACGACCATCCAGGACCTGCGG SCR F  TGCTCACCAGCAGAAATGGT 
 
R  TCCCACTTGGCCCCTCAGCGTA 
 
R  AGGTAGGAGTGCCGCTTCTC 
AQPR1 F  GGCCAGCGAGTTCAAGAAGAA SSTR F  GAAAAGCAAAGATGTCACACTGGA 
 
R  TCACACCATCAGCCAGGTCAT 
 
R  TTGGCATAGCGGAGGATGAC 
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Term P Value 
CO
M
M
O
N
 
GO:0060429~epithelium development 3E-05 
GO:0005902~microvillus 0.002 
GO:0007264~small GTPase mediated signal transduction 0.006 
GO:0005923~tight junction 0.012 
GO:0035295~tube development 0.019 
GO:0006820~anion transport 0.019 
GO:0006821~chloride transport 0.026 
GO:0005792~microsome 0.036 
EC
O
s O
N
LY
 
GO:0006096~glycolysis 1E-04 
GO:0031667~response to nutrient levels 4E-04 
GO:0034329~cell junction assembly 5E-04 
GO:0007584~response to nutrient 0.002 
GO:0007155~cell adhesion 0.009 
GO:0001558~regulation of cell growth 0.014 
GO:0042127~regulation of cell proliferation 0.016 
GO:0008083~growth factor activity 0.039 
PR
IM
AR
Y 
O
N
LY
 
GO:0009611~response to wounding 5E-08 
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